<DOC>
	<DOC>NCT00503698</DOC>
	<brief_summary>This trial is conducted in Africa, Asia, Europe, North and South America and Oceania. The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.</brief_summary>
	<brief_title>The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis</brief_title>
	<detailed_description>The decision to discontinue the trial is not due to safety concerns. The discontinuation is based on an analysis of the significant delay in recruitment of patients which is expected to have a negative impact on the outcome of the trial.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<criteria>Serum albumin as specified in protocol Malnourished (based on serum albumin value below 40 g/L, assessed centrally) Stable (for 3 months or more) and adequate haemodialysis treatment three months prior to enrolment as defined by Kt/V of more than 1.2 Active malignant disease Critical illness requiring treatment in an intensive care unit (ICU) Uncontrolled treated/untreated hypertension Patients on chronic (more than 3 months) treatment with steroids in doses of more than 10 mg/day prednisolone (or equivalent) Patients treated with immunosuppressive agents Known Growth Hormone Deficiency Patients suffering from any clinically significant disease history in the opinion of the investigator Severe illness as defined in the protocol (as judged by the investigator)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>